Tags
- Abacavir
- Abbas Hussein
- Abbott
- Accupril
- Actos
- Acusphere
- Adcock Ingram
- Adderall
- ADHD
- Adverse Drug Reactions
- Adverse events
- advertising spending
- Advisory panels
- Aetna
- AIDS
- Alcon
- Alex Gorsky
- Almirall
- Altace
- Altus Pharmaceuticals
- Alzheimer's
- American Red Cross
- AmerisourceBergen
- Amgen
- Amylin
- analysts
- Andrew Bodnar
- Andrew von Eschenbach
- Andrew Witty
- Anemia
- Anemia drugs
- Angiotech
- antidepressant
- Antidepressants
- antipsychotics
- Apollo Hospital Group
- Approvable letter
- Approval process
- Aranesp
- Artes Medical
- Arthritis
- Arthur Higgins
- Arthur Levinson
- Asia
- AspenBio Pharma
- AsraZeneca
- asthma
- AstraAeneca
- Astrazeneca
- Australia
- Avandia
- Avastin
- Aventis Pharmaceuticals
- Azor
- Barack Obama
- Barr Pharmaceuticals
- Bart
- Bart Stupak
- Baxter
- Bayer
- Bentley Pharmaceutical
- Bernard Poussot
- Bextra
- Big Pharma
- Bill Weldon
- Bill Wells
- Bimeda Groups
- Biogen Idec
- Biosite
- Biotech analyst
- Biotech company news
- biotech IP
- biotech jobs
- biotech new
- Biovail
- birth control
- blockbuster
- BMS
- Bob Essner
- Boston Scientific
- Bradley
- Bradley Pharma
- brain drain
- Brand Name Drugs
- Brazil
- Bristol-Myers Squibb
- Busulfex
- Buyout
- buyouts
- Byetta
- Canada
- cancer vaccine
- Candela
- Cardene
- cardiovascular risks
- Catalent Pharma
- CDC
- CDER
- Ceftobiprole
- Celebrex
- Celgene
- CellCept
- ceo pay
- Cephalon
- Cervarix
- CFO
- Chantix
- Charles Grassley
- Chelsea Therapeutics
- Children
- China
- Chris Viehbacher
- Chron's disease
- Cialis
- Cimzia
- Cipla
- Clarinex
- Claritin
- class action
- Cleveland BioLabs
- CME
- comeback
- Compulsory licensing
- Comtan
- Conflict of interest
- Congress
- Contraceptive
- contract manufacturing
- Controversy
- COO
- Cordaptive
- Coreg
- Counterfeit drugs
- CRO
- Cubicin
- cyclic lipopeptides
- Cymbalta
- Cypher
- Cypress Bioscience
- Cytogen
- Dabur Pharma
- Daiichi Sankyo
- Daniel Vasella
- Daniel Vasellas
- database
- David Brennan
- David Shedlarz
- David Stout
- DEA
- Deborah Autor
- defibrillator
- Democrats
- Depomed
- Detrol
- developing world
- Diabetes
- diagostic tests
- Dialysis
- Dilantin
- Diovan
- Direct to consumer advertising
- Disclosure
- discrimination
- Dr Reddy's
- Dr. Reddy's Laboratories
- drug abuse
- Drug advertising
- Drug coated stents
- Drug combo
- drug costs
- drug development
- Drug Discovery
- Drug launches
- Drug Marketing
- drug prices
- drug safety
- drug-coated stents
- DTC advertising
- Duragesic
- Durect
- earnings
- Economic development
- effectiveness
- Effexor XR
- Eisai
- Elan
- Elder Pharmaceuticals
- Eli Lilly
- EMEA
- EMEA approval
- emerging markets
- Enbrel
- ENHANCE
- ENHANCE trial
- Enrico Veltri
- Epogen
- Erbitux
- Eric Winer
- Eugene Melnyk
- Europe
- European approval
- Evista
- Exubera
- Famvir
- FDA
- FDA approval
- FDA approval & regulation
- FDA approval Clifford J. Rosen
- FDA news
- FDA recalls
- FDA regulation
- FDA update
- FDA warning
- fentanyl
- Fentora
- Fibromyalgia
- Flemming Lindeløv
- FluMist
- Forest Laboratories
- Fosamax
- Frank Baldino
- Frank D'Amelio
- Franz Humer
- Fred Hassan
- gabapentin
- Gardasil
- Gene Logic
- Genentech
- generic
- generic competition
- Generic drugs
- Generic Initiative for Value and Efficiency
- Generics
- Genetic profile
- Genetic screening
- Genzyme
- Gerard Le Fur
- ghostwriting
- Gilead
- GlaxoSmithKline
- Glivec
- Guidant
- H. Lundbeck
- Hana Biosciences
- Hank McKinnell
- Hanston
- health insurance
- heartburn
- Hemo-Stream
- Hemosense
- Henry Waxman
- heparin
- Herb Kohl
- Herceptin
- Hilary Clinton
- HIV
- Hollis-Eden
- hormone replacement therapy
- hostile takeover
- HRT
- Humana
- Humira
- Ian Read
- identity theft
- ImClone
- IMS Health
- incontinence
- Indevus
- India
- Indonesia
- Industry Voices
- innovation
- insulin
- Interpharm
- Inverness Medical Innovations
- Iomai
- IP Rules
- Ipsen Pharmaceuticals
- Ireland
- Italy
- Ixempra
- Jack Tsao
- Jacobs Engineering
- JAMA
- James Cornelius
- James Stein
- Janet Woodcock
- Japan
- Jean-Luc Bélingard
- Jean-Pierre Garnier
- Jeffrey Kindler
- Jerome Kassirer
- Jim Connolly
- job cuts
- Joe Jimenez
- John Dingell
- John Johnson
- John Kasteltein
- John Lechleiter
- Johnson & Johnson
- Joseph Ross
- Judge William Young
- Juergen Schwiezer
- King Pharmaceuticals
- lawsuit
- lawsuits
- layoffs
- legislation
- Levitra
- Lexapro
- Lipitor
- Lobbyists
- Lucentis
- Lundbeck
- lung cancer
- Lupin
- Lyrica
- MabThera
- Malaysia
- Management
- manufacturing
- Maraviroc
- Marck Senak
- Mark McDade
- Mark Senak
- Matritech
- Medco Health Solutions
- medical device
- medical device news
- Medical school
- Medicare
- MediciNova
- MedImmune
- Medtronic
- Melissa DelBello
- Memory Pharmaceuticals
- meningitis
- Menopause
- Merck
- Merck Kgaa
- Merck Serono
- merger
- Mergers & Acquisitions
- MGI Pharma
- Mike Leavitt
- Miles White
- Mircera
- MRSA
- Myfortic
- Mylan
- Nastech Pharmaceuticals
- National Institutes of Health
- natrecor
- Nektar Therapeutics
- Neuronin
- New Jersey Supreme Court
- New York
- New Zealand
- New Zeland
- Newron
- Nexavar
- Nexium
- Nexmed
- NHS
- Niaspan
- Nigeria
- NIH
- Novartis
- Obagi Medical
- off-label marketing
- Omrix Biopharmaceuticals
- Oncologists
- Oncology drugs
- OneOncology
- Orchid Chemicals
- Orencia
- origin labeling
- Orion
- Ortho Evra
- OTC
- outsourcing
- outsourcing China
- OxyContin
- Pain drugs
- pain patch
- Painkiller patch
- Painkillers
- Par Pharmaceuticals
- Parkinson's
- Patches
- Patent
- patent expirations
- Patent news
- Patents
- Paulo Costa
- Payments
- PDL BioBioPharma
- PDUFA
- Perdue Pharma
- PerkinElmer
- Perrigo
- Personalized medicine
- Peter Libby
- Pfizer
- Pharma growth
- pharma jobs
- Pharma news
- Pharma reps
- Pharma Stocks
- pharmaceutical news
- Pharmaceutical sales and marketing
- pharmacies
- Pharmacovigilance
- Pharmion
- Pharmos
- pipeline
- Plan B
- plant expansion
- Plavix
- PML
- PolyMedica
- post-approval marketing
- post-marketing
- Pozen
- Premier Research
- prescribing data
- Prevacid
- Prexige
- Pristiz
- Procrit
- profits
- Protonix
- Provigil
- public trust
- Puerto Rico
- Purdue
- QAS
- Questcor
- R&D
- R&D spending
- Ranbaxy
- Rasilez
- Razadyne
- Rebif
- Reclast
- Regulators
- Relcast
- Repligen
- Republicans
- Retavase
- Rezulin
- rheumatoid arthritis
- Richard Blumenthal
- Richard Clark
- Rigel Pharmaceuticals
- Risperdal
- Ritalin
- Robert Berolini
- Robert Coury
- Robert Parkinson
- Roche
- Rudy Giuliani
- Rumor
- Sam Waksal
- Sanofi-Aventis
- Scherin- Plough
- Schering
- Schering-Plough
- Schizophrenia
- Scotland
- Scott Gottleib
- security breach
- Selzentry
- Sermo
- Seroquel
- Seroquel XR
- Severin Schwan
- SGX Pharmaceuticals
- Shire
- side effects. FDA warning
- Sidney Taurel
- Simcor
- Simon Lowth
- Singapore
- Singulair
- Sol Barrer
- Solaraze
- Sonus Pharmaceutical
- spinoff
- SSRI
- St. Jude Medical
- staph
- State Of Minnesota
- Statins
- Stent
- Stents
- Steven Glason
- Stock
- Stocrin
- Stupak
- suicides
- Sun Pharmaceuticals
- Superbugs
- supply chain
- Supreme Court
- Switzerland
- Symbicort
- Takeda
- Takeover
- talent
- Tamiflu
- Tarceva
- Taxus
- Tekturna
- Tenofovir
- Teva
- Teva Pharmaceuticals
- Thailand
- Threshold Pharmaceuticals
- Transparency
- Trasylol
- Trends
- Trovan
- Tysabri
- UCB Pharma
- UK
- Ulf Wiinberg
- UnitedHealth
- University Of Miami
- Vaccine
- vaccine plant
- Valstar
- Vanda Pharmaceuticals
- Vaniqua
- Velcade
- Ventana
- Verispan
- ViaCell
- Viagra
- Vioxx
- Vytorin
- Walgreen's
- Warfarin
- Watson Pharmaceuticals
- Wellbutrin XL
- Werner Wenning
- West Pharmaceutical Services
- whistleblower
- William Ringo
- Wockhardt
- Wolters Kluwer Health
- Wyeth
- Xeloda
- Xenoport
- Xolair
- Yasmin
- Yusuf Hamied
- Zantac
- Zars Pharma
- Zelnorm
- Zocor
- Zyprexa
- Zyrtek
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight